Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 25 000 UNITS IN SODIUM CHLORIDE 0 9 versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 25 000 UNITS IN SODIUM CHLORIDE 0 9 versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% vs MAGNESIUM SULFATE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III (ATIII) via a unique pentasaccharide sequence, inducing a conformational change that accelerates ATIII-mediated inactivation of coagulation factors IIa (thrombin), Xa, IXa, XIa, and XIIa. The heparin-ATIII complex primarily inhibits thrombin and factor Xa, with higher molecular weight heparin more effectively inactivating thrombin.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
For therapeutic anticoagulation, administer 18 units/kg/hour intravenous infusion after a bolus of 80 units/kg. For prophylactic dosing, 5000 units subcutaneously every 8 to 12 hours.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
None Documented
None Documented
Terminal half-life: 1-2 hours (dose-dependent: 30-60 min after IV bolus 100 U/kg, up to 2-3 hours with higher doses or continuous infusion). Clearance is biphasic; prolonged in hepatic/renal impairment.
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Renal: 40-60% unchanged via urine (dose-dependent saturable mechanism); hepatic: minimal; fecal: negligible.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Category A/B
Category C
Electrolyte
Electrolyte